Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

References

• MokdadAHBowmanBAFordESVinicorFMarksJSKoplanJPThe continuing epidemics of obesity and diabetes in the United StatesJAMA2001286101195120011559264
   PubMed Web of Science ®Google Scholar
• FlegalKMKalantar-ZadehKOverweight, mortality and survivalObesity (Silver Spring)20132191744174523929522
   PubMed Web of Science ®Google Scholar
• WaddenTButrynMWilsonCLifestyle modification for the management of obesityGastroenterology200713262226223817498514
   PubMed Web of Science ®Google Scholar
• KraschnewskiJLBoanJEspositoJLong-term weight loss maintenance in the United StatesInt J Obes (Lond)201034111644165420479763
   PubMed Web of Science ®Google Scholar
• FroehlichJO’MalleySHyytiaPDavidsonDFarrenCPreclinical and clinical studies on naltrexone: what have they taught each other?Alcohol Clin Exp Res200327353353912658121
   PubMed Web of Science ®Google Scholar
• BodnarRJEndogenous opioids and feeding behavior: a 30-year historical perspectivePeptides200425469772515165728
   PubMed Web of Science ®Google Scholar
• LevineASBillingtonCJOpioids as agents of reward-related feeding: a consideration of the evidencePhysiol Behav2004821576115234591
   PubMed Web of Science ®Google Scholar
• GreenwayFLWhitehouseMJGuttadauriaMRational design of a combination medication for the treatment of obesityObesity (Silver Spring)2009171303918997675
   PubMed Web of Science ®Google Scholar
• AtkinsonRLBerkeLKDrakeCRBibbsMLWilliamsFLKaiserDLEffects of long-term therapy with naltrexone on body weight in obesityClin Pharmacol Ther19853844194224042525
   PubMed Web of Science ®Google Scholar
• GreenwayFLDunayevichETollefsonGComparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placeboJ Clin Endocrinol Metab200994124898490619846734
   PubMed Web of Science ®Google Scholar
• LawrenceKRAdraMGillmanPKSerotonin toxicity associated with the use of linezolid: a review of postmarketing dataClin Infect Dis200642111578158316652315
   PubMed Web of Science ®Google Scholar
• DiMartiniAIsoniazid, tricyclics and the “cheese reaction”Int Clin Psychopharmacol19951031971988675973
   PubMed Web of Science ®Google Scholar
• CercatoCRoizenblattVALeancaCCA randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjectsInt J Obes (Lond)200933885786519564877
   PubMed Web of Science ®Google Scholar
• LangloisKJForbesJABellGWGrantGFJrA double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesityCurr Ther Res Clin Exp19741642892964208343
   PubMed Web of Science ®Google Scholar
• AndersonJWGreenwayFLFujiokaKGaddeKMMcKenneyJO’NeilPMBupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trialObes Res200210763364112105285
   PubMedGoogle Scholar
• JainAKKaplanRAGaddeKMBupropion SR vs placebo for weight loss in obese patients with depressive symptomsObes Res200210101049105612376586
   PubMedGoogle Scholar
• CookRJSackettDLThe number needed to treat: a clinically useful measure of treatment effectBMJ199531069774524547873954
   PubMed Web of Science ®Google Scholar
• ApovianCMAronneLRubinoDA randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)Obesity (Silver Spring)201321593594323408728
   PubMed Web of Science ®Google Scholar
• GreenwayFLFujiokaKPlodkowskiRAEffect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLancet2010376974159560520673995
   PubMed Web of Science ®Google Scholar
• WaddenTAForeytJPFosterGDWeight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trialObesity (Silver Spring)201119111012020559296
   PubMed Web of Science ®Google Scholar
• HollanderPGuptaAKPlodkowskiREffects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetesDiabetes Care201336124022402924144653
   PubMed Web of Science ®Google Scholar
• TekCRatliffJReutenauerEGanguliRO’MalleySSA randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of conceptJ Clin Psychopharmacol201434560861225102328
   PubMed Web of Science ®Google Scholar
• CroftHHouserTLJamersonBDEffect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeksClin Ther200224466267212017410
   PubMed Web of Science ®Google Scholar
• Contrave®[prescription information]Deerfield, ILTakeda Pharmaceuticals America I2014 Available from: http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&CountryC-ode=US&LanguageCode=EN&cacheRandomizer=cecb72e0-e3b9-44c7-80a1-3534965d5e61Accessed February 2, 2016
   Google Scholar
• WaddenTAStunkardAJHandbook of Obesity TreatmentNew York, NYGuilford Press2002
   Google Scholar
• HsuWCAranetaMRKanayaAMChiangJLFujimotoWBMI cut points to identify at-risk Asian Americans for type 2 diabetes screeningDiabetes Care201538115015825538311
   PubMed Web of Science ®Google Scholar
• ShiwakuKAnuuradEEnkhmaaBKitajimaKYamaneYAppropriate BMI for Asian populationsLancet20043639414107715051297
   PubMed Web of Science ®Google Scholar
• ZundelNIkramuddinSRosenthalROptimizing outcomes in bariatric surgery: a primer in patient selectionJ Obes2012201283721623304466
   PubMedGoogle Scholar
• BeharyPCeglaJTanTMBloomSRObesity: lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormonesPostgrad Med2015127549450226040552
   PubMed Web of Science ®Google Scholar
• McClendonKSRicheDMUwaifoGIOrlistat: current status in clinical therapeuticsExpert Opin Drug Saf20098672774419998527
   PubMed Web of Science ®Google Scholar
• SweetingANTabetECatersonIDMarkovicTPManagement of obesity and cardiometabolic risk – role of phentermine/extended release topiramateDiabetes Metab Syndr Obes20147354424550678
   PubMedGoogle Scholar
• ZhongXZhangTLiuYEffects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: a network meta-analysisDiabetes Res Clin Pract2015109345146026233934
   PubMed Web of Science ®Google Scholar
• CampbellIWComparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?Int J Clin Pract201064679180120518953
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
   PubMed Web of Science ®Google Scholar
• AstrupACarraroRFinerNSafety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInt J Obes (Lond)201236684385421844879
   PubMed Web of Science ®Google Scholar
• TsaiAGRandomised controlled trial: liraglutide for weight loss: more research is neededEvid Based Med2010152464720436119
   PubMedGoogle Scholar
• MarreMShawJBrandleMLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)Diabet Med200926326827819317822
   PubMed Web of Science ®Google Scholar
• PrelipceanMSO’NeilPJBellDSHyperinsulinemic hypoglycemia precipitated by weight lossSouth Med J200598772672816108243
   PubMed Web of Science ®Google Scholar
• ThaseMEHaightBRJohnsonMCA randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertensionJ Clin Psychopharmacol200828330230718480687
   PubMed Web of Science ®Google Scholar
• PattersonRNHerityNAAcute myocardial infarction following bupropion (Zyban)QJM2002951585911834777
   PubMed Web of Science ®Google Scholar
• CaillierBPiloteSCastonguayAQRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profileFundam Clin Pharmacol201226559960821623902
   PubMed Web of Science ®Google Scholar
• TrippACBupropion, a brief history of seizure riskGen Hosp Psychiatry201032221621720302998
   PubMed Web of Science ®Google Scholar
• JohnstonJALineberryCGAscherJAA 102-center prospective study of seizure in association with bupropionJ Clin Psychiatry199152114504561744061
   PubMed Web of Science ®Google Scholar
• RosenquistPBMcCallWVFarahAReboussinDMEffects of caffeine pretreatment on measures of seizure impactConvuls Ther19941021811858069645
   PubMedGoogle Scholar
• CarrilloJABenitezJClinically significant pharmacokinetic interactions between dietary caffeine and medicationsClin Pharmacokinet200039212715310976659
   PubMed Web of Science ®Google Scholar
• MorrisPBFerenceBAJahangirECardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of CardiologyJ Am Coll Cardiol201566121378139126383726
   PubMed Web of Science ®Google Scholar
• PicciottoMRMineurYSNicotine, food intake, and activation of POMC neuronsNeuropsychopharmacology201338124523147487
   PubMed Web of Science ®Google Scholar
• TollBALearyVWuRSaloveyPMeandzijaBO’MalleySSA preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gainAddict Behav200833117317917587504
   PubMed Web of Science ®Google Scholar
• WilcoxCSOskooilarNEricksonJSAn open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjectsAddict Behav201035322923419926400
   PubMed Web of Science ®Google Scholar
• KimSWGrantJEYoonGWilliamsKARemmelRPSafety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatientsClin Neuropharmacol2006292777916614539
   PubMed Web of Science ®Google Scholar
• XiangXAnRObesity and onset of depression among U.S. middle-aged and older adultsJ Psychosom Res201578324224825553601
   PubMed Web of Science ®Google Scholar
• McElroySLGuerdjikovaAIKimDDNaltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot studyPrim Care Companion CNS Disord201315312 m01494
   Google Scholar
• PatelRReissPShettyHDo antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort studyBMJ Open2015512e008341
   PubMed Web of Science ®Google Scholar
• LeverichGSAltshulerLLFryeMARisk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizersAm J Psychiatry2006163223223916449476
   PubMed Web of Science ®Google Scholar
• TekCKucukgoncuSGuloksuzSWoodsSWSrihariVHAnnamalaiAAntipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medicationsEarly Interv Psychiatry Epub5122015
   Web of Science ®Google Scholar
• GeorgeTPVessicchioJCTermineAA placebo controlled trial of bupropion for smoking cessation in schizophreniaBiol Psychiatry2002521536112079730
   PubMed Web of Science ®Google Scholar
• KumarSKodelaSDetweilerJGKimKYDetweilerMBBupropion-induced psychosis: folklore or a fact? A systematic review of the literatureGen Hosp Psychiatry201133661261721872337
   PubMed Web of Science ®Google Scholar
• Hassanian-MoghaddamHAfzaliSPooyaAWithdrawal syndrome caused by naltrexone in opioid abusersHum Exp Toxicol201433656156723690227
   PubMed Web of Science ®Google Scholar
• HaneyMRameshDGlassAPavlicovaMBediGCooperZDNaltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokersNeuropsychopharmacology201540112489249825881117
   PubMed Web of Science ®Google Scholar
• MannelliPPeindlKPatkarAAWuLTPaeCUGorelickDAReduced cannabis use after low-dose naltrexone addition to opioid detoxificationJ Clin Psychopharmacol201030447647820631574
   PubMed Web of Science ®Google Scholar
• ComerSDMogaliSSacconePAEffects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusersNeuropsychopharmacology201338122427243823736314
   PubMed Web of Science ®Google Scholar
• CorderySFTavernerARidzwanIEA non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigmAddict Biol201419457558623240906
   PubMed Web of Science ®Google Scholar
• WeeSVendruscoloLFMisraKKSchlosburgJEKoobGFA combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependenceSci Transl Med20124146146ra110
   Web of Science ®Google Scholar
• KillianLMDochertyJRCardiovascular stimulant actions of bupropion in comparison to cocaine in the ratEur J Pharmacol2014735323724755144
   PubMed Web of Science ®Google Scholar
• LiangpunsakulSRelationship between alcohol intake and dietary pattern: findings from NHANES IIIWorld J Gastroenterol201016324055406020731019
   PubMed Web of Science ®Google Scholar
• AntonRFOrosziGO’MalleySAn evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) studyArch Gen Psychiatry200865213514418250251
   PubMed Web of Science ®Google Scholar
• de ZwaanMBinge eating disorder and obesityInt J Obes Relat Metab Disord200125Suppl 1S51S5511466589
   PubMed Web of Science ®Google Scholar
• PalavrasMAHayPTouyzSComparing cognitive behavioural therapy for eating disorders integrated with behavioural weight loss therapy to cognitive behavioural therapy-enhanced alone in overweight or obese people with bulimia nervosa or binge eating disorder: study protocol for a randomised controlled trialTrials20151657826683478
   PubMed Web of Science ®Google Scholar
• AugerRRSleep-related eating disordersPsychiatry (Edgmont)2006311647020877520
   PubMedGoogle Scholar
• WhiteMAGriloCMBupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry201374440040623656848
   PubMed Web of Science ®Google Scholar
• NedeltchevaAVScheerFAMetabolic effects of sleep disruption, links to obesity and diabetesCurr Opin Endocrinol Diabetes Obes201421429329824937041
   PubMedGoogle Scholar
• AlamILewisKStephensJWBaxterJNObesity, metabolic syndrome and sleep apnoea: all pro-inflammatory statesObes Rev20078211912717300278
   PubMed Web of Science ®Google Scholar
• SethiMParikhMBariatric surgery versus intensive medical weight management for type 2 diabetesAdv Surg201549115717126299497
   PubMedGoogle Scholar